CMV viral load kinetics as surrogate endpoints after allogeneic transplantation

BACKGROUND: Viral load (VL) surrogate endpoints transformed development of HIV and hepatitis C therapeutics. Surrogate endpoints for CMV-related morbidity and mortality could advance development of antiviral treatments. Although observational data support using CMV VL as a trial endpoint, randomized...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Invest
Главные авторы: Duke, Elizabeth R., Williamson, Brian D., Borate, Bhavesh, Golob, Jonathan L., Wychera, Chiara, Stevens-Ayers, Terry, Huang, Meei-Li, Cossrow, Nicole, Wan, Hong, Mast, T. Christopher, Marks, Morgan A., Flowers, Mary E., Jerome, Keith R., Corey, Lawrence, Gilbert, Peter B., Schiffer, Joshua T., Boeckh, Michael
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2021
Предметы:
Clinical Medicine
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7773411/
https://ncbi.nlm.nih.gov/pubmed/32970635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI133960
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы